



Tandem Diabetes Care to Webcast Investor & Analyst Day on September 25, 2018

September 12, 2018

SAN DIEGO--(BUSINESS WIRE)--Sep. 12, 2018-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced it will host an Institutional Investor and Analyst Day from 8:30am to 1:00pm Pacific Time on Tuesday, September 25, 2018 in San Diego, California. The program will include presentations regarding the Company's longer-term vision, product pipeline, and international expansion. In addition, presentations will be given by clinical and industry experts on the subject of automated insulin delivery (AID). The Company will also host a healthcare provider and patient panel, provide product demonstrations, and will offer tours of its new manufacturing facility.

Institutional investors and analysts are invited to attend live and are encouraged to register in advance at <http://investor.tandemdiabetes.com/institutional-investor-analyst-day>. A live webcast and archived recording of the presentations by members of management and clinical and industry thought leaders will be accessible on Tandem Diabetes Care's Investor Center website located at <http://investor.tandemdiabetes.com> in the "Events & Presentations" section. The remainder of the event will not be webcast. An archive of the recorded portion of the event will be available for 30 days.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2™ Insulin Pump with Basal-IQ™ technology. The t:slim X2 Pump is capable of remote feature updates using a personal computer and is the only automated insulin delivery device approved for children as young as 6 years old. Tandem is based in San Diego, California.

Tandem Diabetes Care is a registered trademark, and t:slim X2 and Basal-IQ are trademarks of Tandem Diabetes Care, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180912005387/en/>

Source: Tandem Diabetes Care, Inc.

For Tandem Diabetes Care, Inc.

Media Contact:

Steve Sabicer, 714-907-6264
ssabicer@thesabicergroup.com

or

Investor Contact:

Susan Morrison, 858-366-6900 x7005
ir@tandemdiabetes.com